Pfefferle Aline, Huntington Nicholas D
Biomedicine Discovery Institute and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
oNKo-Innate Pty Ltd., Clayton, VIC 3800, Australia.
Cancers (Basel). 2020 Mar 17;12(3):706. doi: 10.3390/cancers12030706.
The clinical success stories of chimeric antigen receptor (CAR)-T cell therapy against B-cell malignancies have contributed to immunotherapy being at the forefront of cancer therapy today. Their success has fueled interest in improving CAR constructs, identifying additional antigens to target, and clinically evaluating them across a wide range of malignancies. However, along with the exciting potential of CAR-T therapy comes the real possibility of serious side effects. While the FDA has approved commercialized CAR-T cell therapy, challenges associated with manufacturing, costs, and related toxicities have resulted in increased attention being paid to implementing CAR technology in innate cytotoxic natural killer (NK) cells. Here, we review the current landscape of the CAR-NK field, from successful clinical implementation to outstanding challenges which remain to be addressed to deliver the full potential of this therapy to more patients.
嵌合抗原受体（CAR）-T细胞疗法治疗B细胞恶性肿瘤的临床成功案例，使免疫疗法成为当今癌症治疗的前沿领域。它们的成功激发了人们对改进CAR构建体、识别更多可靶向抗原以及在广泛的恶性肿瘤中进行临床评估的兴趣。然而，伴随着CAR-T疗法令人兴奋的潜力而来的是严重副作用的真实可能性。虽然美国食品药品监督管理局（FDA）已批准CAR-T细胞疗法商业化，但与制造、成本和相关毒性相关的挑战导致人们越来越关注在先天性细胞毒性自然杀伤（NK）细胞中应用CAR技术。在此，我们综述了CAR-NK领域的当前状况，从成功的临床应用到仍有待解决的突出挑战，以便将这种疗法的全部潜力带给更多患者。
